Biotechnology
After Lilly and AbbVie, Haisco Picks Nuvectis Pharma for $1.46B Deal Spanning Two Late-Stage Assets with Best-in-Class Potential
Nuvectis Pharma (NASDAQ: NVCT) just joined Lilly, AbbVie, and Merck as a Haisco in-licensor, acquiring ex-China rights to two late-stage assets for $40M upfront and up to $1.42B in milestones - a PNH drug with 7x superiority over Soliris in Phase 3, and a next-gen BRAF inhibitor for $20B+ markets.
